NCT03058289: A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

NCT03058289
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Chemotherapy, Other, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable untreated metastatic brain or meningeal tumors that do not require treatment
https://ClinicalTrials.gov/show/NCT03058289

Comments are closed.

Up ↑